Stress and Cortisol

Table of Contents

  1. The Short Answer
  2. What the Human Trial Actually Showed
  3. Why This Is Not a Stress Trial
  4. The Dopamine–HPA Mechanism
  5. Antioxidant and Metal-Chelating Activity
  6. What the Animal Work Does and Does Not Show
  7. What “Adaptogen” Is Supposed to Mean
  8. A Fair Comparison: Ashwagandha and Rhodiola
  9. Why It Is the Wrong Tool for an Overstimulated Nervous System
  10. Who Should Not Take Mucuna
  11. If You Try It Anyway: Practical Notes
  12. Measuring Your Own Cortisol
  13. What Would Change the Picture
  14. Key Research Papers
  15. Connections
  16. Featured Videos

The Short Answer

Search for “Mucuna pruriens” and “stress” and you will find the herb described as an adaptogen — something that helps your body cope with pressure, lowers cortisol, and steadies you out. Supplement labels lean on that word heavily.

Here is what is actually behind it. There is one human study, from one research group in Lucknow, India, and it was not a stress trial. It was a male fertility study. The men in it were selected because they were infertile and stressed, and the stress measures were secondary outcomes alongside sperm counts and seminal antioxidant enzymes. It had no placebo arm. It ran for three months in 60 men. That is the entire human cortisol evidence base for this plant.

Everything else you will read on the subject is either laboratory chemistry — Mucuna extract does scavenge free radicals in a test tube, and it does bind iron — or animal work in models of Parkinson's disease and brain injury, not models of psychological stress.

So the honest summary is this:

The rest of this page walks through each of those claims, with the numbers, and ends with a plain list of who should not take this herb at all.

What the Human Trial Actually Showed

The study everyone cites is Mucuna pruriens Reduces Stress and Improves the Quality of Semen in Infertile Men, published by Shukla, Mahdi, Ahmad and colleagues at King George's Medical University in Lucknow. It appeared in Evidence-Based Complementary and Alternative Medicine in 2010, having been published online in late 2007.

The design, in plain terms

What the researchers found

At baseline, the stressed infertile men differed from the fertile controls in several directions at once. They had lower sperm counts and lower sperm motility. Their serum cortisol was elevated. Their seminal fluid showed high lipid peroxide — a marker of oxidative damage to fats — alongside depleted glutathione and vitamin C and reduced activity of two antioxidant enzymes, superoxide dismutase and catalase.

After three months on the seed powder, the paper reports that Mucuna:

The authors' conclusion was that the herb “not only reactivates the anti-oxidant defense system of infertile men but it also helps in the management of stress and improves semen quality.”

One detail worth being precise about

People frequently quote a specific percentage drop in cortisol from this study. The published abstract does not contain one. It describes cortisol as elevated at baseline — it was part of how subjects were selected — and it describes stress as ameliorated after treatment. The numeric cortisol change lives in the paper's own tables, not in the abstract, and the figure that circulates online is often unattributed.

If you see a confident percentage anywhere, ask where it came from. This site's position is that a number you cannot trace is not a number.

The companion papers from the same group

Two other studies from the same Lucknow department fill in the picture, and both are worth knowing about because they are frequently cited as if they were independent confirmation. They are not independent — they share authors, a setting, and a patient pipeline.

That last paper matters for the stress story, because lowering prolactin is exactly what a dopamine agonist does — dopamine is the brain's brake on prolactin release. It is a coherent, mechanistically sensible finding, and it tells you the levodopa in the seed powder was doing something real and measurable in these men.

Why This Is Not a Stress Trial

It is worth spelling out why a fertility study showing lower stress scores is weaker evidence for stress relief than it looks. Each of these points would independently stop a drug regulator from accepting the claim.

1. There was no placebo group

Everyone in the treatment arm got Mucuna. The comparison was against fertile men who received nothing, and against the patients' own baseline. Stress questionnaires are among the most placebo-responsive instruments in medicine — people entered into a study, seen regularly by doctors, given something to take daily and told it will help, reliably report less stress. That is not cynicism; it is the reason placebo arms exist. In the ashwagandha and Rhodiola trials discussed below, the placebo groups also improved, and the real question was whether the herb beat them.

2. Cortisol was an entry criterion, which invites regression to the mean

Men were enrolled because their cortisol was high. Cortisol is a famously variable hormone: it swings with time of day, sleep, illness, caffeine, the stress of a blood draw, and the anxiety of an infertility work-up. If you select people at the top of a fluctuating distribution and measure them again three months later, the average will fall even if you do nothing at all. That is the single most common reason uncontrolled before-and-after studies of stress markers look impressive.

3. The confounding runs the wrong way

These were men in the middle of an infertility investigation — one of the more distressing situations a couple goes through — and their sperm counts improved during the study. It is entirely plausible that their stress fell because the thing that was stressing them got better, and that cortisol followed the good news rather than the capsule. Without a control group that also improves, a trial cannot tell those apart.

4. Stress was a secondary outcome, and nobody has replicated it

The study was powered and designed around semen parameters. Secondary outcomes in a small, unblinded study are hypothesis-generating — the reason to run the proper trial, not a substitute for it. And every human data point on Mucuna and cortisol traces to the same department in the same university: no independent group has repeated it, in any population, with or without a placebo.

None of this means the finding is wrong. It means the correct description is “an unreplicated secondary outcome from a small uncontrolled fertility study” — and the correct description is what belongs on a label.

The Dopamine–HPA Mechanism

The proposed mechanism is the strongest part of the adaptogen argument, so it deserves a fair hearing before the caveats.

How the stress axis works

Cortisol is the end product of a three-step chain called the hypothalamic–pituitary–adrenal (HPA) axis:

  1. The hypothalamus releases corticotropin-releasing hormone (CRH).
  2. CRH tells the pituitary to release adrenocorticotropic hormone (ACTH).
  3. ACTH tells the adrenal glands, sitting on top of your kidneys, to make cortisol.
  4. Cortisol then feeds back to the hypothalamus and pituitary to shut the chain down — a thermostat.

Chronic stress is, in the usual telling, a thermostat that has stopped responding properly: the feedback loop becomes less sensitive, and the system runs hot for longer than it should.

Where dopamine touches the axis

Dopamine neurons in the hypothalamus sit close to this machinery, and dopamine signalling influences it in several ways. The clearest and least disputed is prolactin: hypothalamic dopamine travels to the pituitary and continuously suppresses prolactin release. Take dopamine away and prolactin rises; add a dopamine agonist and prolactin falls. The 2009 Lucknow paper found exactly that fall after Mucuna, which is good evidence that the levodopa reached its target.

Beyond prolactin, dopamine also participates in how the brain appraises a stressor. Dopamine in the mesolimbic system encodes motivation and the expectation of reward. A person with adequate dopamine tone meets a difficult task as a challenge; a person with depleted tone meets the same task as a threat, because nothing feels worth the effort. Threat appraisal is what drives CRH release. So a plausible chain runs: more dopamine → better motivation and appraisal → less perceived threat → less CRH → less ACTH → less cortisol.

Where that argument gets thin

Two problems.

First, the chain is inferred, not measured. Nobody has shown, in humans taking Mucuna, that CRH or ACTH change, or that the feedback sensitivity of the axis changes. What was measured was a cortisol value and a questionnaire score, three months apart, in men whose lives had improved.

Second, dopamine's relationship with the stress axis is not one-directional. Acute stress increases dopamine release in parts of the prefrontal cortex, and stimulant drugs that raise dopamine and noradrenaline generally raise cortisol rather than lowering it. Amphetamine raises cortisol. Caffeine raises cortisol. The 2009 paper found that Mucuna raised adrenaline and noradrenaline as well as dopamine — and adrenaline and noradrenaline are the chemistry of the fight-or-flight response, not of calm.

That is an awkward fact for the adaptogen story, and it is rarely mentioned. A herb that raises circulating catecholamines is doing something closer to what a stimulant does. In a depleted, exhausted man, raising them may well be restorative. In a person who is already running hot, it is the opposite of what is wanted.

Antioxidant and Metal-Chelating Activity

The second pillar of the adaptogen claim is that Mucuna is an antioxidant, and that oxidative stress and psychological stress are linked. Both halves of that are partly true and worth unpacking separately.

The in vitro chemistry is solid

Dhanasekaran, Tharakan and Manyam at Auburn University published the clearest characterisation, in Phytotherapy Research in 2008. Working with Mucuna in the test tube, they showed it:

The iron-binding result is the interesting one. Free divalent iron is not just an innocent bystander in oxidative damage — it is a catalyst. Through the Fenton reaction it converts relatively mild hydrogen peroxide into the hydroxyl radical, which is one of the most destructive species in biology. A compound that sequesters loose iron prevents damage upstream, rather than mopping up radicals one at a time after they form. That is a genuinely more efficient kind of antioxidant activity, and it is a mechanistically sensible reason to be interested in this plant.

Tripathi and Upadhyay at Banaras Hindu University reached compatible conclusions in 2002 using an alcohol extract of the seeds: it inhibited iron-induced lipid peroxidation in rat liver homogenate and removed superoxide and hydroxyl radicals by direct chemical interaction.

The part that gets left out

The same 2002 paper ran a 30-day feeding study in healthy albino rats at doses up to 600 mg/kg. It found no toxicity — and also no change. Liver lipid peroxidation markers, glutathione and superoxide dismutase were unchanged. Liver enzymes were unchanged.

That is exactly what you would expect, and it is the most useful sentence in the paper for a reader trying to decide whether to take this: in a healthy animal that is not under oxidative stress, an antioxidant has nothing to correct. The benefit shows up only where there is damage to reverse — which is precisely the pattern seen in the human fertility study, where the men had depleted glutathione and suppressed antioxidant enzymes at the start.

Does antioxidant activity equal stress relief?

Only loosely. Chronic psychological stress does raise oxidative burden, and the Lucknow work showed that stressed infertile men had measurably worse redox chemistry in seminal fluid. Restoring that is a real result.

But a lipid peroxide level in semen is not a feeling, and no one has shown that improving it makes a person less anxious or less overwhelmed. Antioxidant capacity is measured in every plant food anyone has ever assayed — blueberries, coffee, green tea, amla, rosemary. If in vitro radical scavenging made something an adaptogen, the category would be meaningless. See Antioxidants for how limited these bench assays are as predictors of anything that happens in a person.

What the Animal Work Does and Does Not Show

There is a reasonable body of rodent work on Mucuna and oxidative damage in the brain. It is worth reading, but it is worth reading for what it is.

Notice what is missing. Every one of these is a model of neurotoxic or ischaemic injury. None of them is a model of psychological stress. The standard rodent paradigms for that — chronic restraint stress, chronic unpredictable mild stress, social defeat, forced swim — are well established and widely used, and they have been applied to ashwagandha, to Rhodiola rosea, to ginseng and to many other candidate adaptogens.

Searching the indexed literature for Mucuna pruriens combined with restraint stress returns essentially nothing. The obvious animal experiment for an adaptogen claim has not been done, or has not been published. That is a striking gap for a plant this heavily marketed as a stress herb, and it is much more informative than any of the neuroprotection papers.

What “Adaptogen” Is Supposed to Mean

The word has been diluted to the point of uselessness on supplement labels, so it is worth recovering the original definition — because Mucuna fails it on a specific, checkable point.

The term came from Soviet pharmacology in the mid-twentieth century, and Panossian and Wikman's 2010 review in Pharmaceuticals is the standard modern account of the mechanisms. Three criteria were required:

  1. Non-specific resistance. It should increase resistance to a broad range of stressors — physical, chemical, biological — rather than doing one narrow thing.
  2. Normalising, in both directions. This is the crucial one. An adaptogen should push a disturbed system back toward its set point whichever way it has drifted — lowering what is too high and raising what is too low.
  3. Harmless in ordinary use. It should not meaningfully disturb normal physiology at sensible doses, and should not carry the dependence or crash profile of a stimulant.

Criterion 2 is where Mucuna clearly fails. Mucuna is a levodopa delivery system. Levodopa raises dopamine. It does that in everyone who takes it, in a dose-dependent way, whether their dopamine tone was low, normal or already high. It is a one-directional intervention — a pharmacological agent, not a regulator.

Criterion 3 is also shaky. Levodopa at sufficient dose reliably disturbs normal physiology: nausea, insomnia, agitation, and at the extreme, psychosis. The Katzenschlager crossover study in Parkinson's patients measured this directly — 30 g of Mucuna seed powder produced peak plasma levodopa concentrations 110% higher than standard levodopa/carbidopa 200/50 mg, with an area under the curve 165% larger. That is not a gentle botanical background effect. That is a drug dose, and it behaves like one.

Criterion 1 — broad non-specific resistance — has simply never been tested for Mucuna.

So: one criterion failed on mechanism, one shaky, one untested. Mucuna is a dopaminergic herb that has been filed under “adaptogen” because that is a better-selling word.

A Fair Comparison: Ashwagandha and Rhodiola

The point of this comparison is not to run down Mucuna. It is to show what the evidence looks like when an herb actually has been tested for stress, so you can see the difference in kind rather than in degree.

Ashwagandha (Withania somnifera)

Ashwagandha has multiple randomised, double-blind, placebo-controlled trials in which serum cortisol was a stated outcome and the participants were enrolled for stress, not for something else.

Note what those three have that the Mucuna study does not: placebo control, blinding, a stress-defined population, cortisol as a planned outcome, more than one research group, and a dose–response relationship. Two of them also found improved sleep, which matters enormously for the person actually asking the question.

Rhodiola rosea

Rhodiola's evidence is more mixed than ashwagandha's, and it is useful precisely because of that — it shows what a partially positive literature looks like.

The Olsson result is the sharpest contrast with Mucuna, because it used the cortisol awakening response — the surge in cortisol in the first half hour after you wake up. That is a far better index of HPA-axis regulation than a single daytime blood draw, precisely because it measures the axis's responsiveness rather than its level at one arbitrary moment.

Putting it side by side

If a reader wants the one-line version: ashwagandha has been tested for the thing it is sold for; Mucuna has not. That does not make Mucuna useless. It makes the specific claim — adaptogen, cortisol-lowering, stress-reducing — unsupported at the standard the comparison herbs meet.

Why It Is the Wrong Tool for an Overstimulated Nervous System

This is the part that matters most in practice, and it is the reason this page exists rather than a shorter one.

The word “stress” covers two nearly opposite states, and people reach for the same shelf for both.

The wired, overstimulated presentation

Racing thoughts. Muscle tension. Waking at three in the morning. A heart that thumps at nothing. Irritability. Inability to sit still or to switch off. Too much input, too much vigilance, too much noradrenaline.

For this person, Mucuna is a bad idea, and predictably so. Levodopa is stimulating. The known dose-related adverse effects of levodopa and dopamine agonists read like a list of exactly what this person already has:

And the 2009 Lucknow paper adds the mechanistic seal: Mucuna raised adrenaline and noradrenaline along with dopamine. Giving more catecholamines to someone whose problem is catecholamine excess is the wrong direction, whatever the label says.

The flat, depleted presentation

Nothing feels worth doing. Getting out of a chair takes negotiation. Not sad exactly — blank. Late-stage burnout, the phase after the wired phase burns out.

This is where Mucuna is at least biologically plausible, because low dopamine tone is a good fit for anhedonia and amotivation. It is also, not coincidentally, the profile of the men in the fertility study — who had measurably low dopamine, adrenaline and noradrenaline at baseline.

But plausible is not proven. No trial has tested Mucuna in burnout, in depression with prominent anhedonia, or in any psychological-stress population. And the flat and wired states are not always distinct: a great many exhausted people are both, cycling between them, and dopaminergic stimulation in that situation tends to amplify the wired half.

What to reach for instead

If the picture is overstimulation and poor sleep, the tools with a better fit and better evidence are:

If the symptoms are severe, persistent, or include panic attacks, see Anxiety, and treat an herb as an adjunct rather than a plan.

Who Should Not Take Mucuna

This list is short and it is not negotiable. Mucuna delivers a real dose of a real drug, and the interactions below are pharmacological, not hypothetical.

Also use caution — meaning talk to a clinician first — if you have peptic ulcer disease, cardiovascular disease or arrhythmia, narrow-angle glaucoma, diabetes on medication (Mucuna can lower blood glucose and shift insulin requirements), or if you are taking an SSRI or SNRI. Stop it well before any surgery requiring general anaesthesia, and mention it to the anaesthetist regardless.

A note on the plant itself: the hairs on the seed pod contain mucunain and are a potent contact irritant — the plant's common name is “velvet bean,” but its other common name is “cowitch.” This is a hazard of handling raw pods, not of properly processed seed powder, but it is why the raw material should not be handled casually.

If You Try It Anyway: Practical Notes

Plenty of readers will weigh the above and decide to try it — typically for motivation and drive rather than for calm. That is a defensible choice for a healthy adult who is not on the exclusion list. If you make it, make it carefully.

Measuring Your Own Cortisol

People reading about cortisol often want to test theirs. See Cortisol for the full detail; the short version is why a single number rarely answers the question:

Symptoms that genuinely suggest adrenal disease — unexplained weight gain with purple stretch marks and easy bruising, or profound fatigue with low blood pressure, salt craving and darkening skin — need a doctor and proper testing, not a herb.

What Would Change the Picture

This page is deliberately sceptical, so it is fair to state what would change the conclusion. One study would do it: a randomised, double-blind, placebo-controlled trial, in a population defined by stress rather than by infertility, with cortisol as a pre-specified primary outcome measured properly (serial salivary samples capturing the awakening response and diurnal slope, not one blood draw), using a standardised, assayed preparation so the levodopa dose is known, run by a group independent of the original investigators, and reporting sleep and agitation as safety outcomes since those are the predicted harms.

None of that is exotic — it is the design ashwagandha has been through repeatedly. Until somebody runs it, “Mucuna lowers cortisol” remains an interesting hypothesis generated by a fertility study, and this site will describe it that way.

Key Research Papers

  1. Shukla KK, Mahdi AA, Ahmad MK, Jaiswar SP, Shankwar SN, Tiwari SC. Mucuna pruriens Reduces Stress and Improves the Quality of Semen in Infertile Men. Evidence-Based Complementary and Alternative Medicine. 2010;7(1):137–144. — The single human study behind every cortisol claim: 60 stressed infertile men, 5 g/day seed powder, 3 months, no placebo arm. PMID: 18955292
  2. Shukla KK, Mahdi AA, Ahmad MK, Shankhwar SN, Rajender S, Jaiswar SP. Mucuna pruriens improves male fertility by its action on the hypothalamus-pituitary-gonadal axis. Fertility and Sterility. 2009;92(6):1934–1940. — Measured the catecholamines directly: dopamine, adrenaline and noradrenaline all rose, prolactin and FSH fell. The mechanistic backbone, and the source of the awkward finding that Mucuna raises stress hormones. PMID: 18973898
  3. Ahmad MK, Mahdi AA, Shukla KK, Islam N, Jaiswar SP, Ahmad S. Effect of Mucuna pruriens on semen profile and biochemical parameters in seminal plasma of infertile men. Fertility and Sterility. 2008;90(3):627–635. — The seminal antioxidant work; notable for honestly reporting that motility was not restored to normal in asthenozoospermic men. PMID: 18001713
  4. Dhanasekaran M, Tharakan B, Manyam BV. Antiparkinson drug — Mucuna pruriens shows antioxidant and metal chelating activity. Phytotherapy Research. 2008;22(1):6–11. — The cleanest in vitro characterisation: DPPH and ABTS scavenging, inhibition of lipid and deoxyribose oxidation, divalent-iron chelation, and no genotoxicity on plasmid DNA. PMID: 18064727
  5. Tripathi YB, Upadhyay AK. Effect of the alcohol extract of the seeds of Mucuna pruriens on free radicals and oxidative stress in albino rats. Phytotherapy Research. 2002;16(6):534–538. — Inhibited iron-induced lipid peroxidation in vitro; in healthy rats fed up to 600 mg/kg for 30 days, nothing changed — the useful negative result. PMID: 12237810
  6. Yadav SK, Prakash J, Chouhan S, Singh SP. Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochemistry International. 2013;62(8):1039–1047. — Representative of the animal literature: a toxin model of Parkinson's, not a model of psychological stress. PMID: 23562769
  7. Nayak VS, Kumar N, D'Souza AS, Nayak SS, Cheruku SP, Pai KSR. The effects of Mucuna pruriens extract on histopathological and biochemical features in the rat model of ischemia. NeuroReport. 2017;28(18):1195–1201. — Another injury model rather than a stress model. PMID: 28953092
  8. Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(12):1672–1677. — The pharmacokinetic reality check: 30 g of seed powder gave peak plasma levodopa 110% higher, and an AUC 165% larger, than levodopa/carbidopa 200/50 mg. PMID: 15548480
  9. Infante ME, Perez AM, Simao MR, Manda F, Baquete EF, Fernandes AM, Cliff JL. Outbreak of acute toxic psychosis attributed to Mucuna pruriens. The Lancet. 1990;336(8723):1129. — The documented psychiatric harm. Short, and the reason the psychosis and bipolar exclusions on this page are not theoretical. PMID: 1978001
  10. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012;34(3):255–262. — 64 chronically stressed adults, 300 mg twice daily for 60 days; stress scales P < 0.0001 and serum cortisol P = 0.0006 versus placebo. The comparison standard. PMID: 23439798
  11. Salve J, Pate S, Debnath K, Langade D. Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study. Cureus. 2019;11(12):e6466. — Three arms and a dose–response: cortisol fell at both 250 and 600 mg/day, and sleep quality improved. PMID: 32021735
  12. Lopresti AL, Drummond PD, Smith SJ. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Examining the Hormonal and Vitality Effects of Ashwagandha (Withania somnifera) in Aging, Overweight Males. American Journal of Men's Health. 2019;13(2):1557988319835985. — A crossover design, in which each man serves as his own control. PMID: 30854916
  13. Olsson EM, von Schéele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Medica. 2009;75(2):105–112. — 60 people, 576 mg/day, 28 days. Both arms improved; Rhodiola beat placebo on burnout and attention, and altered the salivary cortisol awakening response. PMID: 19016404
  14. Kasper S, Dienel A. Multicenter, open-label, exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms. Neuropsychiatric Disease and Treatment. 2017;13:889–898. — Included because it is widely cited without the qualifier that matters: open-label, no placebo. PMID: 28367055
  15. Panossian A, Wikman G. Effects of Adaptogens on the Central Nervous System and the Molecular Mechanisms Associated with Their Stress-Protective Activity. Pharmaceuticals (Basel). 2010;3(1):188–224. — The standard modern account of what the word “adaptogen” is supposed to mean, and the criteria Mucuna is measured against on this page. PMID: 27713248

Live PubMed searches

  1. Mucuna pruriens, stress and cortisol
  2. Mucuna pruriens antioxidant activity
  3. Adaptogens and cortisol, randomised trials
  4. Levodopa psychiatric adverse effects

Connections

Back to Table of Contents